NCT01917383View on ClinicalTrials.gov

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

September 30, 2014

Conditions
Primary Open-Angle Glaucoma (POAG)Ocular Hypertension (OHT)
Interventions
DRUG

Trabodenoson

Ophthalmic eye drop

DRUG

Latanoprost

Ophthalmic eye drop

DRUG

Timolol

Ophthalmic eye drop

Trial Locations (1)

37620

Chiltern, Bristol

Sponsors
All Listed Sponsors
lead

Inotek Pharmaceuticals Corporation

INDUSTRY

NCT01917383 - A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma | Biotech Hunter | Biotech Hunter